Applicability of a structure-based modelling approach as a tool for in silico screening of oligonucleotides for targeted RNA editing presented at Oligonucleotide Therapeutics Society (OTS) 2018 by Julien Boudet
… Netherlands, Oct. 1, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that the … October 8 – 10, 2015 and the 11 th Annual Meeting of the OligonucleotideTherapeuticsSociety (OTS) in Leiden, The Netherlands, October 11 – 14, …
… the Netherlands, Sept. 06, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … two investor conferences during the month of September. OligonucleotideTherapeuticsSociety During the 12 th Annual Meeting of the …
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagemen
